Bladder dome cancer

Summary

Bladder dome cancer (MONDO:0001380) is a cancer. A subtype of urinary bladder cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bladder dome cancer
Mondo ID	MONDO:0001380
DOID	DOID:11820
SNOMED CT	188240003
UMLS	C0496827
MedGen	141677
Anatomy (UBERON)	UBERON:0006082
Is cancer (heuristic)	yes

Also known as: cancer of fundus of urinary bladder · fundus of urinary bladder cancer · malignant fundus of urinary bladder neoplasm · malignant neoplasm of dome of urinary bladder · malignant neoplasm of fundus of urinary bladder · malignant tumour of vault of bladder

Disease family

This is a subtype of urinary bladder cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › urinary system disorder › urinary bladder disorder › urinary bladder neoplasm › urinary bladder cancer › bladder dome cancer

Related subtypes (8): bladder lateral wall cancer, bladder neck cancer, urinary bladder posterior wall cancer, bladder sarcoma, urinary bladder anterior wall cancer, urachus cancer, bladder lymphoma, urinary bladder carcinoma

Subtypes (2): bladder trigone cancer, ureteric orifice cancer

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.